Table 3.
Univariate analysis for bPFS rate
| Factors | 2-year b-PFS rate (%) | 5-year b-PFS rate (%) | P value |
|---|---|---|---|
| CTV (ml) | |||
| < 50 | 95.4 | 85.3 | 0.985 |
| ≥ 50 | 98.5 | 82.2 | |
| Gleason score | |||
| < 8 | 98.9 | 92.5 | < 0.001 |
| ≥ 8 | 92.5 | 64.5 | |
| PSA at diagnosis (ng/ml) | |||
| < 10 | 94.4 | 86.0 | 0.774 |
| 10–20 | 96.0 | 86.3 | |
| > 20 | 100 | 80.2 | |
| Pre-treatment PSA (ng/ml) | |||
| < 10 | 94.0 | 88.4 | 0.253 |
| 10–20 | 97.8 | 87.1 | |
| > 20 | 100 | 74.2 | |
| Symptoms | |||
| Presented | 98.2 | 85.9 | 0.733 |
| No | 95.8 | 81.5 | |
| NCCN risk grouping | |||
| Low | 100 | 87.5 | |
| Favorable int ermediate | 95.2 | 95.2 | |
| Unfavorable intermediate | 100 | 90.5 | 0.007 |
| High | 97.7 | 86.3 | |
| Very high | 92.1 | 61.6 | |
| Age (years) | |||
| < 70 | 93.4 | 80.0 | 0.903 |
| ≥ 70 | 98.0 | 84.7 | |
| ADT | |||
| Presence | 95.8 | 73.2 | 0.004 |
| Absence | 97.6 | 90.4 |
The bold vaues indicate statistical significance